These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11373772)

  • 1. [Resistance in HIV therapy. Which cases profit from resistance testing].
    Manegold C
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():26-30. PubMed ID: 11373772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance--clinical significance and diagnostics.
    Puchhammer-Stöckl E
    Wien Med Wochenschr; 1998; 148(23-24):556-9. PubMed ID: 10189686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiretroviral therapy 1998/1999: what is our current status?--Avoiding therapy failure instead of expecting it].
    Zangerle R
    Wien Med Wochenschr; 1998; 148(23-24):527-9. PubMed ID: 10189681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral resistance testing for clinical management.
    Youree BE; D'Aquila RT
    AIDS Rev; 2002; 4(1):3-12. PubMed ID: 11998782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
    Aceti A; Carosi G
    Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV resistance testing. A clinical tool.
    Paul SM; Jorden VS
    N J Med; 2003 Sep; 100(9 Suppl):44-9; quiz 75-6. PubMed ID: 14556603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of resistance to antiretroviral therapy in the minority community.
    Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA
    AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance. Navigating resistance pathways.
    Kuritzkes D
    AIDS Read; 2002 Sep; 12(9):395-400, 407. PubMed ID: 12402803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.